Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol/ImClone Pull, Will Resubmit, Erbitux sBLA For Lung Cancer

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

ImClone Systems and Bristol-Myers Squibb are pulling a supplemental BLA for Erbitux (cetuximab) to treat non-small cell lung cancer, saying they plan to resubmit the application as soon as possible after answering manufacturing questions posed by FDA

You may also be interested in...

FDA Agrees To Accelerated Approval For Myozyme Scale-Up, Genzyme Says

The 2,000L version of Myozyme on track for approval with a post-market confirmatory trial in February; user fee date extended while FDA reviews REMS submission.

Amylin Speculation Intensifies: Byetta LAR May Be Delayed

Comparability studies could mean filing is impossible for first half of 2009, Amylin says.

Lilly Snatches ImClone Away From Bristol

Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts